Traumatic PVR prevention and treatment via composite drug film

Abstract This study aimed to develop a composite sustained-release drug film by incorporating triamcinolone acetonide (TA) and daunorubicin (DNR) into a poly-L-lactide caprolactone (P(LLA-CL)) matrix, and to evaluate its in vitro release characteristics, in vivo biocompatibility, and therapeutic efficacy in the treatment of traumatic proliferative vitreoretinopathy (TPVR). P(LLA-CL) was dissolved in hexafluoroisopropanol, weighed TA and DNR powder, and added it to the P(LLA-CL) solution, and then electrospinning was performed on these materials to prepare P(LLA-CL)-TA, P(LLA-CL)-DNR, and P(LLA-CL)-TA-DNR composite drug films. In vitro release experiments were performed on drug films (4 × 8 mm) and corresponding drug powders placed in phosphate-buffered saline (PBS). At fixed time points, samples were collected and drug content was calculated by HPLC to record the cumulative drug release curve. The in vivo safety of the drug films was evaluated by suturing the drug films onto the rabbit eyes sclera, 5 mm away from the limbus, and then observing slit-lamp biomicroscopy, intraocular pressure (IOP), and histopathological changes at fixed time points from 1 week to 6 months after suturing. TPVR was constructed by scleral injury and autologous blood injection, and the rabbits were randomly divided into model, control, P(LLA-CL)-TA, P(LLA-CL)-DNR, and composite drug film groups. The observation indices were fundus photography, HE staining, and immunohistochemistry (IHC) analysis of inflammatory factors TNF-α and TGF-β. In vitro release experiment results showed that the P(LLA-CL)-TA and P(LLA-CL)-DNR drug films released the drugs for 156 and 135 days, and the cumulative drug release rates reached 88.41% and 92.68%, respectively. The composite P(LLA-CL)-TA-DNR drug film released TA and DNR for 141 days (91.54%) and 129 days (89.31%) respectively, which were greatly prolonged compared with the release time of the drugs powders (48 days and 4 days for TA and DNR, respectively). In vivo experiment results showed that no ocular toxicity or IOP elevation was induced by the drug films. The gradual degradation of drug films was observed during the six-month observation period. In therapeutic application, the composite drug film reduced the retinal folding, preretinal membrane formation and TNF-α mean optical density at 2 weeks [(0.426 ± 0.036) vs. (0.518 ± 0.043) in the model group, P < 0.0001] and at 4 weeks [(0.460 ± 0.040) vs. (0.537 ± 0.029), P = 0.0003], and improved the vitreous hemorrhage ( P = 0.0402). P(LLA-CL)-TA-DNR composite drug film can achieve sustained release of therapeutic agents for up to five months. The drug film exhibits a good safety profile, and showed preliminary therapeutic potential to attenuate TPVR progression via suppressing inflammatory response and cellular proliferation. Compared with single-drug films, the composite film showed marginal improvement of vitreous hemorrhage absorption and reduced retinal proliferation.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-15
DOI
https://doi.org/10.1038/s41598-026-78242-6
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Traumatic PVR prevention and treatment via composite drug film

Yuzhen Liu, Kaihui Nan, Mei Chen, Ting Zhu et al.
Scientific Reports
Advanced Drug Delivery Systems
article

Traumatic PVR prevention and treatment via composite drug film

Yuzhen Liu, Kaihui Nan, Mei Chen, Ting Zhu, Xiaolin Wang, Jie Liu
article en

Abstract

Abstract This study aimed to develop a composite sustained-release drug film by incorporating triamcinolone acetonide (TA) and daunorubicin (DNR) into a poly-L-lactide caprolactone (P(LLA-CL)) matrix, and to evaluate its in vitro release characteristics, in vivo biocompatibility, and therapeutic efficacy in the treatment of traumatic proliferative vitreoretinopathy (TPVR). P(LLA-CL) was dissolved in hexafluoroisopropanol, weighed TA and DNR powder, and added it to the P(LLA-CL) solution, and then electrospinning was performed on these materials to prepare P(LLA-CL)-TA, P(LLA-CL)-DNR, and P(LLA-CL)-TA-DNR composite drug films. In vitro release experiments were performed on drug films (4 × 8 mm) and corresponding drug powders placed in phosphate-buffered saline (PBS). At fixed time points, samples were collected and drug content was calculated by HPLC to record the cumulative drug release curve. The in vivo safety of the drug films was evaluated by suturing the drug films onto the rabbit eyes sclera, 5 mm away from the limbus, and then observing slit-lamp biomicroscopy, intraocular pressure (IOP), and histopathological changes at fixed time points from 1 week to 6 months after suturing. TPVR was constructed by scleral injury and autologous blood injection, and the rabbits were randomly divided into model, control, P(LLA-CL)-TA, P(LLA-CL)-DNR, and composite drug film groups. The observation indices were fundus photography, HE staining, and immunohistochemistry (IHC) analysis of inflammatory factors TNF-α and TGF-β. In vitro release experiment results showed that the P(LLA-CL)-TA and P(LLA-CL)-DNR drug films released the drugs for 156 and 135 days, and the cumulative drug release rates reached 88.41% and 92.68%, respectively. The composite P(LLA-CL)-TA-DNR drug film released TA and DNR for 141 days (91.54%) and 129 days (89.31%) respectively, which were greatly prolonged compared with the release time of the drugs powders (48 days and 4 days for TA and DNR, respectively). In vivo experiment results showed that no ocular toxicity or IOP elevation was induced by the drug films. The gradual degradation of drug films was observed during the six-month observation period. In therapeutic application, the composite drug film reduced the retinal folding, preretinal membrane formation and TNF-α mean optical density at 2 weeks [(0.426 ± 0.036) vs. (0.518 ± 0.043) in the model group, P < 0.0001] and at 4 weeks [(0.460 ± 0.040) vs. (0.537 ± 0.029), P = 0.0003], and improved the vitreous hemorrhage ( P = 0.0402). P(LLA-CL)-TA-DNR composite drug film can achieve sustained release of therapeutic agents for up to five months. The drug film exhibits a good safety profile, and showed preliminary therapeutic potential to attenuate TPVR progression via suppressing inflammatory response and cellular proliferation. Compared with single-drug films, the composite film showed marginal improvement of vitreous hemorrhage absorption and reduced retinal proliferation.

Scientific Reports
Central South University (CN), Wenzhou Medical University (CN), Affiliated Eye Hospital of Wenzhou Medical College (CN), Second Xiangya Hospital of Central South University (CN), Aier Eye Hospital Group (China) (CN), Joint Shantou International Eye Center (CN)
Advanced Drug Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon